Furthermore, in the case of antitumoral action, ANXA1 is involved in the inhibition of cell proliferation, promotion of apoptosis, and reduction of cell motility, as shown in breast cancer (triple negative) [55] and prostate cancer [56]. Here, ANXA1 is linked to prostate cancer.